Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

ISENTRESS

RALTEGRAVIR POTASSIUM

Standard Dose
EQ 100MG BASE/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ISENTRESS is listed in Drugs@FDA under application 205786 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient RALTEGRAVIR POTASSIUM Form and strength POWDER;ORAL - EQ 100MG BASE/PACKET Sponsor MSD SUB MERCK Submission history Latest submission status date: 2021-05-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview ISENTRESS is listed in Drugs@FDA under application 205786 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient RALTEGRAVIR POTASSIUM Form and strength POWDER;ORAL - EQ 100MG BASE/PACKET Sponsor MSD SUB MERCK Submission history Latest submission status date: 2021-05-18 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ISENTRESS (RALTEGRAVIR POTASSIUM) | Drug Monograph | MedicHelpline